MA35857B1 - Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k - Google Patents

Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k

Info

Publication number
MA35857B1
MA35857B1 MA37198A MA37198A MA35857B1 MA 35857 B1 MA35857 B1 MA 35857B1 MA 37198 A MA37198 A MA 37198A MA 37198 A MA37198 A MA 37198A MA 35857 B1 MA35857 B1 MA 35857B1
Authority
MA
Morocco
Prior art keywords
pi3k
inhibitors
activity
function
pi3k inhibitors
Prior art date
Application number
MA37198A
Other languages
English (en)
Inventor
Pascal Furet
Frédéric Stauffer
Nigel Graham Cooke
Gomes Dos Santos Paulo Antonio Fernandes
Christina Hebach
Klemens Högenauer
Gregory HOLLINGWORTH
Christoph Kalis
Ian Lewis
Alexander Baxter Smith
Nicolas Soldermann
Ross Strang
Frank Stowasser
Nicola Tufilli
Matt Anette Von
Romain Wolf
Frédéric Zecri
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35857B1 publication Critical patent/MA35857B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne de nouvelles utilisations d'inhibiteurs de pi3k, lesdits inhibiteurs de pi3k ayant une action inhibitrice sur l'isoforme delta de pi3k pour le traitement d'une immunopathologie chez un sujet souffrant d'une maladie ou d'un trouble choisi parmi la malaria, la leishmaniose, la trypanosomiase, la toxoplasmose et/ou la neurocysticercose, par inhibition fonctionnelle de tlr9 du sujet infecté.
MA37198A 2011-12-15 2014-07-11 Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k MA35857B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161576194P 2011-12-15 2011-12-15
PCT/IB2012/057332 WO2013088404A1 (fr) 2011-12-15 2012-12-14 Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k

Publications (1)

Publication Number Publication Date
MA35857B1 true MA35857B1 (fr) 2014-12-01

Family

ID=47603895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37198A MA35857B1 (fr) 2011-12-15 2014-07-11 Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k

Country Status (24)

Country Link
US (1) US9949979B2 (fr)
EP (1) EP2790705B1 (fr)
JP (1) JP6117235B2 (fr)
KR (1) KR102038462B1 (fr)
CN (1) CN103998042B (fr)
AP (1) AP3849A (fr)
AU (1) AU2012354094C1 (fr)
BR (1) BR112014014327A2 (fr)
CA (1) CA2857302C (fr)
DK (1) DK2790705T3 (fr)
EA (1) EA029473B1 (fr)
ES (1) ES2661510T3 (fr)
GT (1) GT201400114A (fr)
HU (1) HUE036052T2 (fr)
MA (1) MA35857B1 (fr)
MX (1) MX351530B (fr)
NI (1) NI201400056A (fr)
NO (1) NO2896266T3 (fr)
PH (1) PH12014501348A1 (fr)
PL (1) PL2790705T3 (fr)
PT (1) PT2790705T (fr)
SI (1) SI2790705T1 (fr)
TN (1) TN2014000230A1 (fr)
WO (1) WO2013088404A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
AU2013343291B2 (en) 2012-11-07 2018-05-10 Karus Therapeutics Ltd Novel histone deacetylase inhibitors and their use in therapy
ES2688815T3 (es) 2013-05-10 2018-11-07 Karus Therapeutics Limited Inhibidores de histona desacetilasa novedosos
ES2818933T3 (es) * 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
AU2014361800B2 (en) 2013-12-13 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2015089479A1 (fr) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Procédé pour traiter un lymphome lymphoplasmocytaire
WO2015162584A1 (fr) 2014-04-24 2015-10-29 Novartis Ag Formes cristallines du sel de sulfate de n-[5-(3-imidazol-1-yl-4-méthanesulfonyl-phényl)-4-méthyl-thiazol-2-yl]-acétamide
CA2965178C (fr) 2014-10-22 2023-09-26 Dana-Farber Cancer Institute, Inc. Composes contenant des groupes thiazolyle pour le traitement de maladies proliferatives
GB201419228D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
GB201419264D0 (en) 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
EP3762368B1 (fr) 2018-03-08 2022-01-26 Incyte Corporation Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
CN112313217A (zh) * 2018-06-19 2021-02-02 诺华股份有限公司 氰基三唑化合物及其用途
JPWO2020017569A1 (ja) 2018-07-17 2021-12-02 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
US20220226299A1 (en) 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
WO2023170680A1 (fr) 2022-03-08 2023-09-14 Equashield Medical Ltd Station de transfert de fluide dans un système de préparation pharmaceutique robotique
CN114957676B (zh) * 2022-06-22 2023-05-16 安徽工程大学 一种利用反溶剂沉积快速调控水分活度制备美拉德反应产物的方法

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300645A (en) 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
AU2001257571A1 (en) 2000-05-10 2001-11-20 Icos Corporation Phosphatidyl inositol 3-kinase delta binding partner
DE10043667A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
KR100916613B1 (ko) 2000-11-07 2009-09-14 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
EP1389617B1 (fr) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Compose heterocyclique et agent antitumoral contenant ce dernier en tant qu'ingredient actif
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
PL376844A1 (pl) 2002-12-09 2006-01-09 The Board Of Regents Of The University Of Texas System Sposoby selektywnego hamowania kinazy tyrozynowej 3 z grupy Janus (JAK3)
KR20050087865A (ko) 2002-12-27 2005-08-31 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물
WO2005016348A1 (fr) 2003-08-14 2005-02-24 Icos Corporation Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
MXPA06008257A (es) 2004-01-23 2006-08-31 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
WO2005086814A2 (fr) * 2004-03-09 2005-09-22 The Uab Research Foundation Procedes et compositions relatifs a la regulation de la production de cytokine par la glycogene synthase kinase 3 (gsk-3)
WO2005112935A1 (fr) 2004-05-13 2005-12-01 Vanderbilt University Inhibiteurs sélectifs de la phosphoinositide-3-kinase delta pour inhiber l'angiogenèse
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MXPA06014478A (es) 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
ES2552804T3 (es) 2005-05-04 2015-12-02 Evotec Ag Compuestos heterocíclicos condensados, y sus composiciones y usos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
NZ565749A (en) 2005-08-26 2010-12-24 Serono Lab Pyrazine derivatives and use as PI3K inhibitors
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US20070197509A1 (en) 2005-12-21 2007-08-23 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
GB0612630D0 (en) 2006-06-26 2006-08-02 Novartis Ag Organic compounds
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
BRPI0714614A2 (pt) 2006-07-28 2013-05-14 Novartis Ag quinazolina 2,4-substituÍdas como inibidores de lipÍdeos cinase
EP1891958A1 (fr) 2006-08-03 2008-02-27 Universite Pierre Et Marie Curie (Paris Vi) Inhibiteurs des kinases Rho/Rock/PI3/Akt pour le traitement des maladies associé aux parasites protozoaires
US20100216820A1 (en) 2006-11-13 2010-08-26 White Stephen L Thienopyrimidiones for treatment of inflammatory disorders and cancers
MX2009009913A (es) 2007-03-23 2009-10-16 Amgen Inc Derivados de quinolina o benzopirazina y sus usos para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias o varias clases de canceres.
WO2008118455A1 (fr) 2007-03-23 2008-10-02 Amgen Inc. Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k)
KR101504773B1 (ko) 2007-03-23 2015-03-20 암젠 인크 헤테로시클릭 화합물 및 그의 용도
ES2566387T3 (es) 2007-04-02 2016-04-12 Evotec Ag Compuestos heterocíclicos condensados de pirid-2-ilo, y composiciones y usos de los mismos
GB0707087D0 (en) 2007-04-12 2007-05-23 Piramed Ltd Pharmaceutical compounds
EP2150546B1 (fr) 2007-04-12 2011-01-19 F. Hoffmann-La Roche AG Dérivés de pyrimidine comme inhibiteurs de la phosphatidylinositol-3-kinase
KR20100016431A (ko) 2007-04-12 2010-02-12 에프. 호프만-라 로슈 아게 약학적 화합물
EP2139334B1 (fr) 2007-04-17 2013-07-03 Evotec AG Composés hétérocycliques fusionnés de 2-cyanophényle, compositions et utilisations de ceux-ci
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2154965A4 (fr) 2007-05-29 2011-08-17 Glaxosmithkline Llc Dérivés de naphtyridine en tant qu'inhibiteurs de p13 kinase
WO2008152387A1 (fr) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Dérivés de quinazoline comme inhibiteurs de pi3 kinase
WO2008152394A1 (fr) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Composés pharmaceutiques
CN101679456B (zh) 2007-06-12 2012-09-05 霍夫曼-拉罗奇有限公司 噻唑并嘧啶类和它们作为磷脂酰肌醇3-激酶的抑制剂的应用
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
RU2341527C1 (ru) 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
WO2009036768A2 (fr) 2007-09-19 2009-03-26 H. Lundbeck A/S Diagnostic de la prise de poids potentielle chez un sujet
WO2009046448A1 (fr) 2007-10-04 2009-04-09 Intellikine, Inc. Entités chimiques et leurs utilisations thérapeutiques
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2009058361A1 (fr) * 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition de la production d'ifn de type i
WO2009064802A2 (fr) 2007-11-13 2009-05-22 Eli Lilly & Co. Inhibiteurs de phosphatidyl-inositol 3-kinase delta humaine
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
WO2009120094A2 (fr) 2008-03-27 2009-10-01 Auckland Uniservices Limited Pyrimidines et triazines substituées, et leur utilisation en thérapie anticancéreuse
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8536169B2 (en) 2008-06-05 2013-09-17 Glaxo Group Limited Compounds
EP2300437B1 (fr) 2008-06-05 2013-11-20 Glaxo Group Limited Dérivés de benzpyrazole en tant qu'inhibiteurs de p13 kinases
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
EP2313399B1 (fr) 2008-06-19 2014-05-28 Millennium Pharmaceuticals, Inc. Dérivés de thiophène ou de thiazole et leur utilisation comme inhibiteurs de pi3k
CA2730271A1 (fr) 2008-07-07 2010-01-14 Xcovery Holding Company Llc Inhibiteurs selectifs des isoformes de la pi3 kinase
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
BRPI0919816A2 (pt) * 2008-09-26 2019-09-24 Eisai R&D Man Co Ltd uso compostos benzoxazólicos no tratamento de malária
WO2010036380A1 (fr) 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
WO2010059593A1 (fr) 2008-11-18 2010-05-27 Intellikine, Inc. Procédés et compositions pour le traitement d'affections ophtalmiques
CA2745280A1 (fr) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Medicaments a ciblage phosphatidylinositol-3-kinase p110 delta dans le traitement des troubles du snc
WO2010102958A1 (fr) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles en tant qu'inhibiteurs des p13 kinases
EP2411391A1 (fr) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomères de dérivés de 2-purinyl-3-tolyl-quinazolinone et procédés d'utilisation
US8293783B2 (en) 2009-03-24 2012-10-23 National University Of Singapore Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (COPD)
WO2010120991A1 (fr) * 2009-04-17 2010-10-21 Wyeth Llc Composés de 5,6,7,8-tétrahydropyrido[4,3-d]pyrimidine, leur utilisation en tant qu'inhibiteurs de kinase mtor, pi3, et hsmg-1, et leurs synthèses
CN102458410A (zh) 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
SI2899191T1 (sl) 2009-04-30 2017-11-30 Glaxo Group Limited Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
EP2427195B1 (fr) * 2009-05-07 2019-05-01 Intellikine, LLC Composés hétérocycliques et leurs utilisations
JP5781066B2 (ja) 2009-05-27 2015-09-16 ジェネンテック， インコーポレイテッド ｐ１１０δに対して選択的な二環式ピリミジンＰＩ３Ｋ阻害剤化合物及び使用方法
US8158625B2 (en) 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
AU2010265971B2 (en) 2009-06-25 2014-08-14 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of PI3 K activity
TW201111362A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
TW201111376A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
MX2011013901A (es) 2009-06-25 2012-05-08 Amgen Inc Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
CN102482286B (zh) 2009-07-02 2015-07-15 赛诺菲 新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途
DK2448939T3 (en) 2009-07-02 2017-06-19 Sanofi Sa DERIVATIVES OF 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ON, PREPARATION AND PHARMACEUTICAL USE thereof
CN102647987A (zh) 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
IN2012DN01325A (fr) 2009-08-20 2015-06-05 Karus Therapeutics Ltd
KR20120081164A (ko) 2009-09-29 2012-07-18 엑스커버리 홀딩 컴퍼니 엘엘씨 Ｐｉ3ｋ(델타) 선택적 억제제
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
DK2496567T3 (en) 2009-11-05 2017-10-30 Rhizen Pharmaceuticals S A PRESENT UNKNOWN BENZOPYRANKINA MODULATORS
CA2779951A1 (fr) 2009-11-06 2011-05-12 Piramal Life Sciences Limited Derives d'imidazopyridine
KR20130049766A (ko) 2009-11-13 2013-05-14 메르크 세로노 에스. 에이. 트리사이클릭 피라졸 아민 유도체
EP2507231A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Dérivés d'indazole comme inhibiteurs des pi3-kinases
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR079529A1 (es) 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
CA2784566A1 (fr) 2009-12-18 2011-06-23 Amgen Inc. Composes heterocycliques et leurs utilisations
US8440651B2 (en) 2010-02-22 2013-05-14 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
RU2013104038A (ru) 2010-07-14 2014-08-20 Ф. Хоффманн-Ля Рош Аг СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ PI3K p110 ДЕЛЬТА ПУРИНОВЫЕ СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP2616469B1 (fr) 2010-09-14 2016-10-26 Exelixis, Inc. Composés dérivés de la 9h-purine comme inhibiteur de pi3k-delta et procédés pour les préparation
US9670212B2 (en) 2010-09-14 2017-06-06 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
CA2825966A1 (fr) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Composes de benzoxazepine selectifs pour pi3k p110 delta et leurs methodes d'utilisation
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
EP2518071A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs PI3K
EP2518070A1 (fr) 2011-04-29 2012-10-31 Almirall, S.A. Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
WO2013057711A1 (fr) * 2011-10-21 2013-04-25 Novartis Ag Dérivés de quinazoline en tant que modulateurs des pi3k
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии

Also Published As

Publication number Publication date
PT2790705T (pt) 2018-01-24
MX351530B (es) 2017-10-18
NO2896266T3 (fr) 2018-04-28
BR112014014327A2 (pt) 2017-06-13
CN103998042A (zh) 2014-08-20
MX2014007164A (es) 2015-03-09
CN103998042B (zh) 2016-12-28
ES2661510T3 (es) 2018-04-02
KR20140107421A (ko) 2014-09-04
AP2014007679A0 (en) 2014-06-30
DK2790705T3 (en) 2018-03-12
HUE036052T2 (hu) 2018-06-28
PL2790705T3 (pl) 2018-06-29
KR102038462B1 (ko) 2019-10-31
NI201400056A (es) 2014-12-22
CA2857302A1 (fr) 2013-06-20
US9949979B2 (en) 2018-04-24
TN2014000230A1 (en) 2015-09-30
SI2790705T1 (en) 2018-03-30
GT201400114A (es) 2015-02-19
AU2012354094B2 (en) 2014-11-20
AU2012354094A1 (en) 2014-07-03
JP6117235B2 (ja) 2017-04-19
WO2013088404A1 (fr) 2013-06-20
EP2790705B1 (fr) 2017-12-06
EA201491182A1 (ru) 2016-01-29
EP2790705A1 (fr) 2014-10-22
EA029473B1 (ru) 2018-03-30
PH12014501348A1 (en) 2014-09-15
AP3849A (en) 2016-09-30
AU2012354094C1 (en) 2015-10-15
CA2857302C (fr) 2020-08-25
JP2015500332A (ja) 2015-01-05
US20150342951A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
MA35857B1 (fr) Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k
CY1119533T1 (el) Νεοι θεραπευτικοι παραγοντες
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
MA47440B1 (fr) Sulfonylurées, composés apparentés, et leur utilisation
MA41014B1 (fr) Composés n-((het)arylméthyl)-hétéroaryl-carboxamides comme inhibiteurs de la kallikréine plasmatique
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
EA201391674A1 (ru) Новые соединения, связывающие фарнезоидный x-рецептор (nr1h4) и модулирующие его активность
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
WO2014152536A3 (fr) Inhibiteurs de la leucotriène a4 hydrolase
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
EA201791929A1 (ru) Гетероциклиламины как ингибиторы pi3k
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
EA201490552A1 (ru) Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
EA201490539A1 (ru) Соединения и композиции в качестве ингибиторов c-kit киназы
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA39147B1 (fr) Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
EA201391591A1 (ru) Лечение множественной миеломы
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
EA201001496A1 (ru) Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
MA42700B1 (fr) Dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate